STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Twice Weekly in Subjects With Hematologic Malignancies

The purpose of this study is to characterize the safety and efficacy of STA-9090 (ganetespib) in subjects with hematologic malignancies.

Inclusion Criteria

• Males and females 18 years or older
• Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol
• Must have acceptable organ function during screening as defined in the protocol

Exclusion Criteria

• Pregnant or breast-feeding women
• Patients must meet the washout periods for prior chemotherapies and radiation
• History of stroke within 6 months of treatment
• Poor venous access for study drug administration
• Treatment with chronic immunosuppressants
• Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation